Astagraf XL
Total Payments
$163,293
Transactions
48
Doctors
14
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $19.16 | 1 | 1 |
| 2022 | $135,779 | 14 | 0 |
| 2017 | $27,496 | 33 | 13 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $135,779 | 14 | 83.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $20,630 | 6 | 12.6% |
| Travel and Lodging | $2,934 | 11 | 1.8% |
| Space rental or facility fees (teaching hospital only) | $2,500 | 2 | 1.5% |
| Food and Beverage | $1,450 | 15 | 0.9% |
Payments by Type
Research
$135,779
14 transactions
General
$27,515
34 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Prospective, Pilot Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release (Astagraf XL) in HLA Sensitized Kidney Transplant Recipients | Astellas Pharma Global Development | $53,494 | 0 |
| A Phase 1b, Multicenter, Dose Escalation, Evaluation of Safety and Tolerability of ASP7317 for Geographic Atrophy Secondary to Age-related Macular Degeneration | Astellas Pharma Global Development | $47,687 | 0 |
| A Staged Study Incorporating a Phase 1b, Multicenter, Unmasked, Dose Escalation Evaluation of Safety and Tolerability and a Phase 2, Multicenter, Unmasked, Randomized, Parallel-group, Controlled, Proof of Concept Investigation of Efficacy and Safety of ASP7317 for Atrophy Secondary to Age-related Macular Degeneration | Astellas Pharma Global Development | $33,037 | 0 |
| A Phase 1b Study of ASP1951, a GITR Agonistic Antibody, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Astellas Pharma Global Development | $1,560 | 0 |
Top Doctors Receiving Payments for Astagraf XL
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Honolulu, HI | $138,279 | 16 |
| , M.D | Transplant Surgery | Tyler, TX | $16,080 | 14 |
| , M.D | Surgery | Washington, DC | $3,287 | 3 |
| , MD | Nephrology | San Francisco, CA | $2,283 | 3 |
| , M.D | Internal Medicine | Webster, TX | $2,140 | 2 |
| , MD | Surgery | Danville, PA | $317.60 | 1 |
| , M.D | Transplant Surgery | Hartford, CT | $125.00 | 1 |
| , MD, PHD | Internal Medicine | San Francisco, CA | $124.55 | 1 |
| , M.D | Nephrology | Long Beach, CA | $124.55 | 1 |
| , MD | Nephrology | Portland, OR | $124.55 | 1 |
| , MD | Nephrology | San Francisco, CA | $124.55 | 1 |
| , MD | Nephrology | Portland, OR | $124.55 | 1 |
| Neha Garg | Nephrology | San Francisco, CA | $124.55 | 1 |
| , MD | Urology | Bristol, TN | $19.16 | 1 |
| , MD | Internal Medicine | Miami, FL | $15.03 | 1 |
Ad
Manufacturing Companies
- Astellas Pharma Global Development $135,779
- Astellas Pharma US Inc $27,515
Product Information
- Type Drug
- Total Payments $163,293
- Total Doctors 14
- Transactions 48
About Astagraf XL
Astagraf XL is a drug associated with $163,293 in payments to 14 healthcare providers, recorded across 48 transactions in the CMS Open Payments database. The primary manufacturer is Astellas Pharma Global Development.
Payment data is available from 2017 to 2024. In 2024, $19.16 was paid across 1 transactions to 1 doctors.
The most common payment nature for Astagraf XL is "Unspecified" ($135,779, 83.2% of total).
Astagraf XL is associated with 4 research studies, including "A Prospective, Pilot Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release (Astagraf XL) in HLA Sensitized Kidney Transplant Recipients" ($53,494).